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Abstract  
The large diversity of peptides from venomous creatures with high affinity for molecules involved in 
the development and maintenance of neuropathic pain has led to a surge in venom-derived 
analgesic research. Some members of the α-conotoxin family from Conus snails which specifically 
target subtypes of nicotinic acetylcholine receptors (nAChR) have been shown to be effective at 
reducing mechanical allodynia in neuropathic pain models. We sought to determine if three such 
peptides, Vc1.1, AuIB and MII were effective following intrathecal administration in a rat 
neuropathic pain model because they exhibit different affinities for the major putative pain relieving 
targets of α-conotoxins. Intrathecal administration of α-conotoxins, Vc1.1, AuIB and MII into 
neuropathic rats reduced mechanical allodynia for up to 6 hours without significant side effects. In 
vitro patch-clamp electrophysiology of primary afferent synaptic transmission revealed the mode of 
action of these toxins was not via a GABAB-dependant mechanism, and is more likely related to their 
action at nAChRs containing combinations of α3, α7 or other subunits. Intrathecal nAChR subunit-
selective conotoxins are therefore promising tools for the effective treatment of neuropathic pain. 
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1. Introduction 
A limitation to effective clinical pain management is the lack of highly specific analgesics that exhibit 
tolerable side effects. The enormous diversity of peptides from Conus snails that target ion channels, 
receptors, and transporters known to be involved in neuropathic pain has led to the search for 
better analgesics based on venom-derived peptides (Lewis and Garcia 2003). The α-conotoxins 
represent one such family that specifically target nicotinic acetylcholine receptor (nAChR) subtypes. 
Owing to the combination of a large variety of nAChR subunit assemblies and subunit-selective α-
conotoxins, many potential novel analgesics have recently been identified (Dutton and Craik 2001; 
Alonso et al. 2003; Sandall et al. 2003; Lang et al. 2005; Satkunanathan et al. 2005; Olivera et al. 
2008; McIntosh et al. 2009) α-Conotoxins, including Vc1.1, RgIA, MII and AuIB, have all been 
reported to potently reverse signs of neuropathic pain, particularly tactile allodynia,  in animal 
models when administered systemically (Satkunanathan et al. 2005; Klimis et al. 2011). 
Some controversy exists as to the mechanisms of anti-allodynia among α-conotoxins.  Early studies 
suggested that interaction with 3 subunit-containing nAChRs may mediate these actions (Livett et 
al. 2006), but the affinity of Vc1.1 and AuIB for these subtypes is rather weak (Clark et al. 2006; 
Vincler et al. 2006). Vc1.1 and RgIA are both potent antagonists of α9α10 nAChRs, suggesting this 
may be the anti-allodynia target (Vincler et al. 2006). However, MII and AuIB are both devoid of 
activity at α9α10 nAChRs (McIntosh et al. 1999; Callaghan et al. 2008; Azam and McIntosh 2009; 
Callaghan and Adams 2010; Klimis et al. 2011) and other -conotoxin analogues that act on these 
nAChRs fail to inhibit allodynia (Nevin et al. 2007). Moreover, 910 nAChRs show very limited 
tissue distribution, being expressed predominantly in the olivochochlear system (Vetter et al., 2007) 
and their role in sensory nerve function is unclear. We have recently shown that Vc1.1, AuIB and 
RgIA inhibit N-type calcium channels in dorsal root ganglion (DRG) neurons through a novel GABAB 
receptor-dependent mechanism distinct from the well-known modulation of these channels by G-
protein β subunits (Callaghan et al. 2008; Callaghan and Adams 2010; Klimis et al. 2011). MII is 
inactive at this target, although it produces partial reversal of allodynia in nerve injured rats (Klimis 
et al. 2011), suggesting this is not the only mechanism.  Taken together, these findings suggest N-
type calcium channels and possibly 3 subunit-containing nAChR may both be important, but it is 
unlikely that α9α10 nAChRs are responsible for pain relief after systemic administration. However, 
α-conotoxins exhibit varying and incompletely characterized selectivity for nAChR comprising 
combinations of α3-, α5- and α6 – and α7-subunits together with different β-subunits  (Clark et al., 
2006; Vincler and McIntosh, 2007). Many of these subunits are expressed by sensory neurons (eg. 
Khan et al. 2003). 
The present study was designed to determine if α-conotoxins with distinct activity profiles at α3- 
(but possibly other α-subunits) or  α9α10-containing  nAChRs  differentially  relieve allodynia 
following intrathecal administration in a neuropathic pain model and, in parallel, if inhibition of N-
type calcium channels in primary afferent nerve terminals through a novel GABAB-receptor-
dependent mechanism is responsible. The α-conotoxins MII, AuIB and Vc1.1 all displayed long-
lasting (up to 6 hours) anti-allodynic activity. In vitro electrophysiological recordings of primary 
afferent-stimulated evoked excitatory post synaptic currents (eEPSCs) onto superficial dorsal horn 
neurons revealed that none of these peptides substantially inhibited primary afferent activity, 
although a conventional GABAB-receptor agonist produced profound presynaptic inhibition.  The 
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findings suggest that neither α9α10 nAChRs nor GABAB-receptor-dependent inhibition of N-type 
calcium channels in primary afferent synapses is the mechanism of action, but intrathecal delivery of 
-conotoxins appears to be a promising therapeutic avenue. 
 
2. Materials and methods 
2.1 Rodents and surgical procedures for establishing neuropathic pain 
All experiments involving animals were approved by the University of Sydney or Royal North Shore 
Hospital/University of Technology Animal Ethics Committees. Experiments were performed under 
the guidelines of the Australian code of practice for the care and use of animals for scientific 
purposes (National Health and Medical Research Council, Australia, 7th Edition). Great care was 
taken to minimise animal suffering during these experiments whenever possible. In vivo experiments 
were performed on 59 male Sprague-Dawley rats weighing 200–260 g. Rats were housed four per 
cage and were maintained on standard 12-h light/dark cycle with free access to food and water. Rats 
underwent partial ligation of the left sciatic nerve (PNL), as previously described (Seltzer et al. 1990). 
In rats that developed significant mechanical allodynia 7 days after surgery, chronic polyethylene 
lumbar intrathecal catheters were inserted between vertebrae L5–6, advanced 3 cm rostrally and 
exteriorized via the occipital region (Storkson et al. 1996). All of these procedures were carried out 
under isoflurane anaesthesia (2.0-2.5% in oxygen). 
2.2 Mechanical allodynia testing 
Mechanical paw withdrawal threshold (PWT) was measured using a series of von Frey hairs with 
bending pressures ranging from 0.41 to 15.1 g. Rats were placed in elevated plastic cages with wire 
mesh bases suspended above a table. All rats were given 30 min to acclimatise to the testing 
environment. Beginning with the 2 g filament, von Frey hairs were pressed perpendicularly against 
the plantar surface of the left hind paw and held for 2 s. Each von Frey filament was applied seven 
times at random locations. A positive response was regarded as the sharp withdrawal of the paw, 
paw licking, or flinching upon removal of the von Frey filament. The mechanical PWT was calculated 
using the up-down paradigm (Dixon 1980). If an animal did not respond to any hairs then the 
mechanical PWT was assigned as 15 g. Mechanical PWT to non-noxious mechanical stimuli were 
tested prior to surgery on day 0 (pre-PNL), 7, and 12-14 following injury. 
2.3 Measurement of motor side effects 
To measure motor side effects, ambulation was tested by measuring the latency to fail negotiation 
of a rotarod device (Ugo Basile, Italy), with a maximal cut-off time of 300 s as previously described 
(Klimis et al. 2011). Each animal was tested immediately prior to intrathecal injection, then 60 and 
120 min after injection. Differences (s) between post- and pre-injection latencies (pre-injection ~ 
120s) were determined for each animal. Each latency recording consisted of the average of three 
measurements on the day of testing. 
2.4 Drugs and intrathecal conotoxin administration 
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The α-conotoxins Vc1.1, AuIB and MII were synthesised as previously described (Schnolzer et al. 
1992; Cartier et al. 1996; Luo et al. 1998; Clark et al. 2006). Briefly, Boc solid phase chemistry was 
used to synthesise, deprotect and cleave from the resin all peptides as described (Schnolzer et al. 
1992). 100 mM ammonium bicarbonate (pH 7.5-8.2) was used to oxidise reduced HPLC-purified 
peptides at room temperature with constant stirring. Finally, each peptide was purified and 
quantified in triplicate using reverse-phase HPLC and an external reference. Intrathecal injections 
were made via the exteriorized catheter 10–12 days after PNL surgery using gentle restraint. 
Peptides were dissolved in 0.9% saline to the desired concentration on the day of the experiment 
and were injected in a volume of 10 µl, followed by 15 µl of 0.9% saline to wash the drug from the 
catheter dead-space. Control animals received injections of the corresponding vehicle. In all 
experiments, the experimenter was blinded to drug treatments. Catheter patency and placement 
was confirmed by the occurrence of brief bilateral hind limb paralysis following intrathecal 
lignocaine (20 µL, 2%, (2-diethylamino-N[2,6-dimethylphenyl]-acetamide; Sigma-Aldrich, Sydney)) 
after all experiments. 
2.5 In vitro electrophysiology 
Spinal cord slices (340 µm) were prepared from isoflurane (4% in air) anaesthetised 12- to 28-day-
old male and female rat pups on a Leica VT1200S vibrating blade microtome in ice-cold modified 
artificial cerebrospinal fluid (ACSF, in mM); choline chloride (120), glucose (11), NaHCO3 (25), KCl 
(2.5), NaH2PO4 (1.4), CaCl2 (0.5), MgCl2 (7), atropine (0.001). Slices were allowed to recover for 1 
hour at room temperature in ACSF (in mM); NaCl (125), KCl (2.5), NaH2PO4 (1.25), NaHCO3 (25), 
glucose (11), MgCl2 (1.2), CaCl2 (2.5) before being transferred to a recording chamber (500 µL) where 
Dodt-contrast optics was used to identify lamina I/II neurons of superficial dorsal horn for patch-
clamp electrophysiology. The internal solution of the recording pipette contained (in mM); CsCl 
(140), EGTA (10), HEPES (5), CaCl2 (2), MgATP (2), NaGTP (0.3), QX314 chloride (5) and had an 
osmolality of 290 mOsm. Drugs were superfused onto slices at a rate of 2 mL per minute in normal 
ACSF at a nominal 33oC. All neurons were voltage-clamped at a nominal holding potential of -60 mV 
(liquid junction potential not corrected). eEPSCs were elicited by stimulating dorsal roots at 0.03Hz 
with bipolar tungsten stimulating electrodes using a stimulus strength sufficient to evoke reliable 
submaximal eEPSCs (usually 100 µs, 5-30 V). All reagents were purchased from Sigma Aldrich 
(Australia) except QX314, which was purchased from Alomone Labs (Israel). 
2.6 Data analysis 
All data were analysed using Prism(R) (GraphPad version 4 for Windows(TM), San Diego, CA, USA). 
For PWTs, two-way ANOVA (time, drug) was performed with Bonferroni post-tests if statistically 
significant effects were found. AUC data were generated using the AUC function in Prism™., with 
Analyses encompassed the pre-injection (time = 0) to 6 hour time poinst and were analysed by one-
way ANOVA with Dunnett’s multiple comparison post-tests. P < 0.05 was considered significant. 
3. Results 
3.1 Effects of Vc1.1, AuIB and MII on PNL-induced mechanical allodynia 
Partial nerve ligation-induced, rapid and long-lasting mechanical allodynia that was maximal by 10–
12 days after surgery (data not shown) as determined by changes to the paw withdrawal threshold 
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(PWT). At day 12–14 post-PNL, α-conotoxins were administered to conscious rats via a chronically 
implanted intrathecal catheter. The small apparent differences between animals randomly assigned 
to the different treatment groups for pre-PNL PWT and post-PNL PWT before injecting conotoxins 
were not significant. Changes in PWT to mechanical stimuli were then tested at set intervals (1, 2, 4 
and 6 hours) to determine anti-nociceptive effects. All three α-conotoxins dose-dependently 
increased the PWT, with significant anti-allodynia persisting for up to 6 hours for all conotoxins 
(Figure 1; 2 nmol). Beginning at 1 hour post-injection, i.t. Vc1.1 increased the PWT significantly at a 
dose of 2 nmol, which lasted for the duration of the experiment (P < 0.001, t = 1,2,4,6). A 10-fold 
lower dose of Vc1.1 (0.2 nmol) also significantly increased PWT beginning at 2 hours (P < 0.05) and 
lasting until 6 hours (P < 0.01 for 4 and 6 hours) post-injection, but the lowest dose of Vc1.1 (0.02 
nmol) had no significant effect. At no time point post-injection did the PWT for the saline-treated 
control group increase. 
Conotoxin MII produced robust anti-allodynic activity at 2 nmol, significantly increasing the PWT 
beginning at 1 hour post-injection (P < 0.01). This effect persisted for up to 6 hours post-injection at 
this dose (P < 0.001 for t = 2, 4 and 6 hours). Lower doses of MII were also found to be anti-allodynic, 
with 0.2 nmol and 0.02 nmol both increasing PWT by 2 hours post-injection (P < 0.05 and P < 0.01, 
resp.), and the lowest dose tested (0.02 nmol) still significantly elevated at 4 hours (P < 0.05). 
AuIB was the least potent conotoxin following a single intrathecal injection. At the highest dose 
tested, AuIB significantly increased PWTs beginning at 1 hour post-injection (P < 0.05) and remained 
elevated for up to 6 hours post-injection (2nmol; P < 0.001 t = 2 and 6 hours, P < 0.01 t = 4 hours).  A 
lower dose (0.2 nmol) also produced a significant increase in PWT at 4 hours post-injection, but the 
lowest dose (0.02 nmol) did not produce significant reversal of tactile allodynia.  
The area under the curve (AUC) was also calculated for each conotoxin (0–6 hours) to determine 
dose–response relationships. All three conotoxins displayed a similar increase in AUC as a function of 
increasing dose. As such, a significant increase in AUC was observed for each conotoxin at 2 nmol (P 
< 0.01; ANOVA with Dunnett’s post-hoc test) 
3.2 Effects of Vc1.1, AuIB and MII on motor impairment 
Rotarod latencies were determined for each dose of intrathecal conotoxin throughout the testing 
period for mechanical allodynia. No significant change to rotarod latency, and therefore no motor 
impairment, was observed for the highest dose of each conotoxin tested (2 nmol; repeated 
measures ANOVA). This suggests motor performance was not impaired and did not confound 
allodynia testing. 
3.3 Effect of Vc1.1, AuIB and MII on evoked EPSCs in spinal cord slices 
Primary afferent eEPSCs in whole-cell patch-clamped neurons of spinal lamina I/II were generated by 
stimulating dorsal roots (0.03Hz) in naive rat spinal cord slices. We superfused 1 µM of each 
conotoxin onto these slices to determine their influence on primary afferent excitatory 
neurotransmission. The representative current traces of AMPA receptor-mediated eEPSCs in Figure 3 
reveal that for α-conotoxin Vc1.1 (1 µM), no significant change to afferent-evoked eEPSCs were 
observed (Figure 3Ai and B) in the presence of picrotoxin (100 µM) and strychnine (5 µM) to block 
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GABAA and glycine receptor-mediated synaptic currents, respectively. eEPSCs were abolished by the 
AMPA receptor antagonist CNQX (10 µM, not shown). This finding is summarised in the histogram in 
Figure 3C. A higher concentration (10 µM) of Vc1.1 was also without effect (97 ± 4% of baseline, N = 
9). As Vc1.1 has been shown to interact with somatic GABAB receptors (Callaghan et al. 2008; 
Callaghan and Adams 2010; Klimis et al. 2011), in some experiments the GABAB agonist baclofen was 
superfused following washout of Vc1.1 (figure 3Ai, 3B). Baclofen (10 µM) markedly reduced eEPSC 
amplitude by 81% (Figure 3C, N = 3). For AuIB and MII, a small but significant reduction in the eEPSC 
was observed (86 ± 4% and 84 ± 3%, resp. N=4 for both). This suggests these two conotoxins may 
modestly reduce glutamatergic neurotransmission in vivo.  
4. Discussion 
The present study has shown that intrathecal delivery of α-conotoxins differentially targeting α3 
subunit-containing, α9α10 nAChR channels and GABAB receptors/N-type calcium channels are anti-
allodynic in rodent models of neuropathic pain. These anti-allodynic effects were not confounded by 
motor deficits because rotarod performance was not impaired. 
Previous studies have shown that nAChR agonists such as nicotine (α4β2) and epibatadine (non- 
α4β2) display anti-allodynic activity in neuropathic pain models (Rashid and Ueda 2002), and that 
these effects are likely due to excitatory actions on GABAergic interneurons in the spinal cord dorsal 
horn (Rashid and Ueda 2002; Genzen and McGehee 2005). 7 (Gao et al. 2010) and perhaps 3 
subunit-containing (Takeda et al. 2003; Gao et al. 2010) nAChRs have also been proposed to make a 
small contribution to nicotinic excitation of dorsal horn GABAergic interneurons. We have previously 
shown that Vc1.1 is anti-allodynic in neuropathic pain models when administered intramuscularly, 
and that sustained reversal of allodynia appears due to GABAB-receptor-dependent inhibition of N-
type Ca2+ channels because it is reversed by a selective GABAB-receptor antagonist (Klimis et al. 
2011). Furthermore, we observed no reversal of allodynia with peripheral administration of two 
analogs of Vc1.1, vc1a and [P60]Vc1.1 that exhibited no activity at GABAB receptor/N-type Ca
2+ 
channels but full activity at α9α10 nAChRs, suggesting that antagonism of α9α10 is not a requisite 
for anti-allodynia (Nevin et al. 2007; Callaghan et al. 2008). However, Vc1.1, AuIB and MII have 
markedly different (> 1000-fold) potencies for GABAB receptors/N-type calcium channels, with MII 
being nearly inactive. We have therefore tentatively attributed the anti-allodynic activity of MII to its 
potent antagonism of α3β2 nAChRs (~ 1 nM) (Klimis et al. 2011) when administered peripherally. It 
remains possible that like Vc1.1, AuIB acts either on GABAB receptors/N-type calcium channels or α3 
subunit-containing nAChR channels, or both. Thus multiple pharmacological targets could mediate 
the anti-allodynic actions of different systemically administered -conotoxins. 
 
On the basis of the actions of peripherally administered -conotoxins, we sought to determine 
whether or not similar actions may be mediated in the spinal cord. A single intrathecal injection of 
each of the three α-conotoxins produced long lasting (up to 6 hours) anti-allodynia with relative 
potency that appears to be in the order MII > Vc1.1 > AuIB.  This order is based on the significant 
peak effects (at 2 hours) of all doses of MII compared with smaller effects of Vc1.1, and particularly 
AuIB at lower doses.  This order of potency is not clearly reflected by the AUC calculations, because 
the duration of action of Vc1.1 and AuIB are longer than found with lower doses (0.02 and 0.2 nmol) 
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of MII. The finding that MII was the most potent anti-allodynic -conotoxin after intrathecal 
administration suggests that α9α10 nAChRs or GABAB receptors/N-type calcium channels are not the 
primary targets for this peptide in the spinal cord, because it has little or no activity at these targets 
(Klimis et al., 2011). AuIB also fails to interact with α9α10 nAChRs, suggesting this nAChR is not 
involved after intrathecal administration. However, we cannot rule out a contribution for Vc1.1, 
which has high affinity for both α9α10 nAChRs and GABAB receptors/N-type calcium channels (Klimis 
et al., 2011). 
It is possible that the anti-allodynic actions of all three -conotoxins are mediated by 3- containing 
nAChRs or other subunit combinations of nAChRs expressed by primary afferent nerve terminals or 
spinal cord. It is unlikely that MII, Vc1.1 and AuIB all produce their intrathecal anti-allodynic actions 
via interaction exclusively with 3β2 or 3β4 nAChRs, because the potency of Vc1.1 and AuIB at 
either of these nAChRs is more than 100-fold weaker than MII (Klimis et al., 2011). Vc1.1 has 
relatively low affinity for 3β2 and 3β4 nAChRs (Clark et al., 2006; Vincler and McIntosh, 2007) but 
may have higher affinity for more complex subunit combinations, e.g. its affinity for 6/32β2β3 
nAChRs is 140 nM (Vincler and McIntosh, 2007). It was therefore suggested that Vc1.1 might 
produce pain relief via inhibition of 3- and/or 5-containing nAChRs on sensory nerves. α3, α4, α5, 
β2 and β4 subunit transcripts are all found in spinal cord parenchyma and sensory ganglia (Khan et 
al. 2003). Although the specificity of nAChR antibodies has been questioned (Moser et al. 2007), the 
subunits all appear to be expressed on primary afferents that co-label immunohistochemically with 
IB4, and with synaptophysin in superficial dorsal horn (Khan et al. 2003). It therefore remains 
possible that pain relief may be achieved after intrathecal administration by antagonism of nAChRs 
comprising complex combinations of α3 with α5, β4 and β2 subunits, perhaps in combination with 
other less common subunits.  However, nAChRs composed of other as yet unidentified subunit 
combinations may be responsible and it will be important to determine the specific combinations 
responsible for these actions. 
Our findings of highly efficacious anti-allodynic actions (von Frey thresholds) of intrathecal MII 
appear at odds with the modest increase in responsiveness to strong mechanical stimuli (Randell-
Selitto test) following intrathecal injection of a very low dose of intrathecal MII (0.1 pmol) in 
untreated rats (Young et al. 2008). The basis for the discrepancies are unclear, but could be due to 
dose, different stimuli employed or effects of nerve injury. The lowest intrathecal dose we tested 
was 20-fold greater than the highest dose examined in rats (Young et al. 2008), which could greatly 
affect distribution of nAChR blockade in the dorsal horn of the spinal cord or primary afferent nerve 
roots. Young et al. (2008) also found no effect of this dose of MII on alldoynia in a nerve injury 
model, but still noted modest hyperalgesia in the uninjured, contralateral paw. This suggests that 
the effects of higher doses we observed may be specific for nerve injury-induced allodynia.  
The finding that even very high concentrations of Vc1.1, MII and AuIB had little effect on the 
amplitude of primary afferent eEPSCs in spinal cord slices suggests that the GABAB receptor-
dependent inhibition of N-type Ca2+ channels we found for -conotoxins Vc1.1 and AuIB (Callaghan 
et al. 2008; Klimis et al. 2011) in rodent DRG neurons is not present at N-type channels in primary 
afferent nerve terminals. This is not particularly surprising, because the conventional mechanism of 
GABAB-receptor agonist inhibition of N-channels via G-protein β-subunits in both DRG cell bodies 
and primary afferent terminals is not responsible for -conotoxin effect on N-type calcium channels 
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in DRG neurons. The actual signalling mechanism is more complex, involving c-Src, but is not yet fully 
understood (Callaghan et al. 2008). It is therefore possible that the signalling mechanism is localised 
to DRG cell bodies, but not their central nerve terminals. 
 
The small reductions in eEPSC amplitudes produced by MII and AuIB may be related to α3 nAChR or 
other expression of different subunit combinations in primary afferents and/or on post-synaptic 
NK1-receptor expressing cells (Cordero-Erausquin et al. 2004). The small inhibitions of eEPSCs 
observed here are unlikely to account for the reversal of allodynia produced by all three -
conotoxins after intrathecal administration, presumably because tonic concentrations of ACh in 
tissue slices are not sufficient to strongly activate nAChRs. Spinal nerve ligation studies have 
suggested that the α3 subunit, which is confined to neuronal perikarya and expressed mostly by 
small, bipolar neurons of superficial laminae, increases bilaterally after injury (Vincler and Eisenach 
2004). Choline acetyl transferase-expressing neurons are abundant in the dorsal horn of the spinal 
cord and innervate multiple cell types, including primary afferents (Ribeiro-da-Silva and Cuello 
1990). Tonic and phasic ACh concentrations in vivo are presumably great enough to activate nAChRs, 
but it is not known if ACh concentrations are elevated in chronic pain states. On the other hand, 
GABA/Glycine interneurons are found to preferentially express α4α6β2 nAChRs, whereas NK1-
receptor/Calbindin-expressing neurons typically co-label with α3β2α7 subunit-containing nAChRs 
(Cordero-Erausquin et al. 2004). Selective antagonists for 3 subunit-containing nAChRs that could 
co-express other nAChR subunits may therefore suppress activation by endogenous ACh of primary 
afferents or pro-nociceptive NK1-receptor/Calbindin expressing neurons. Together, these findings 
suggest that antagonists acting selectively on α3-subunit containing nAChRsbut not α4 – or α9α10 
subunit-containing nAChRs may be promising targets in neuropathic pain. However, it is possible 
that these nAChR antagonists act on other subunit containing nAChRs, such α7 to relieve 
neuropathic pain. 
5. Conclusions 
Here we have shown that α-conotoxins which are applied intrathecally and are known to interact 
with α3* nAChRs, but not α9α10 nAChRs or GABAB receptors/N-type calcium channels, display anti-
allodynic activity in vivo in a neuropathic pain model. This finding implies that drugs (including α-
conotoxins) targeting 3-containing nAChRs, or perhaps other nAChR subunit combinations that 
these conotoxins interact with, may prove to be clinically relevant in the treatment of neuropathic 
pain. 
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Figure captions 
 
Figure 1. Effect of alpha-conotoxins on mechanical allodynia. Time course of the effects of i.t. 
injection of (A) Vc1.1, (B) MII and (C) AuIB on mechanical PWT (left column). Each point represents 
the mean +/- SEM for each time point (Vehicle; n = 6, Vc1.1; n = 7 (2 nmol), 6 (0.2 nmol) and 8 (0.02 
nmol), AuIB and MII; n=6 (2 nmol), 4 (0.2 nmol) and 6 (0.02 nmol)). Time point t = 0 represents PWT 
immediately before injection. The right column shows the corresponding dose-response as AUC for 
each dose of drug between 0 and 6 hours (* = P < 0.05, ** = P < 0.01, *** = P < 0.001, Dunnett’s 
post-hoc tests). 
Figure 2. Effect of alpha-conotoxins on motor performance. Time course of the effects of i.t. 
injection of Vc1.1, MII and AuIB. Each point represents mean +/- SEM change in rotarod latency (s) 
vs. pre-injection (t = 0) latency for highest dose of each drug tested (2 nmol) (Vehicle, AuIB and MII n 
= 6, Vc1.1 n = 7). Lower doses were also without effect. 
Figure 3. Effect of alpha-conotoxins on synaptic transmission. (A) Example current traces from 
dorsal-root stimulated dorsal horn neurons in the presence of (i) Vc1.1, (ii) MII and (iii) AuIB. Each 
trace represents the average of 10 individual episodes for drug (red) vs. baseline (black). In (i) the 
effect of baclofen (10 µM) is also shown (blue). (B) Example time course of the effects of Vc1.1 and 
baclofen superfusion onto spinal cord slices (Bac = 10 µM baclofen). (C) Peak effect of each 
conotoxin and baclofen normalised to baseline eEPSC amplitude (* = P < 0.05; One sample t-test, 
Vc1.1 n= 8, AuIB n = 4, MII n = 4, baclofen n=3). 
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